At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Predictor of Clinical Response to Acthar in Myositis: Phase II of Acthar Clinical Trial
In Brief
An observational study evaluating Healthy Control and Myositis in Remission for Myositis and 2 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Comparing the clinical effects of Acthar Gel before and after treatment and compare it to patients with inactive disease.
Study Details
Timeline
Interventions
Ten healthy adult patients evaluating serum, PBMC's, and RNA.
Ten patients (four who have polymyositis, six dermatomyositis) from our database who are followed in the Myositis Center. We will collect serum, PBMC's, and RNA samples will be obtained at baseline and at six months. Remission is defined as a global myositis disease activity score less than or equal to 1 on the MDAAT assessments with no new immunosuppressive drug or glucocorticoid use and no increase in dose of either in the preceding year.